Target Evalulation
In this product category, you will find reports evaluating targets for drug discovery, either prepared for a target of interest defined by La Merie Publishing or prepared as part of our service offering for customized report preparation specifically defined by clients or for pre-scoped evaluations in which the client selects the target of interest for a standardized evaluation.
Showing all 8 resultsSorted by latest
-
7 working days upon order placementTarget Evaluation for Drug Discovery in Biopharmaceutical R&D: Pre-Scoped Premium Evaluation€ 1000.00
-
5 working days upon order placementTarget Evaluation for Drug Discovery in Biopharmaceutical R&D: Standard Evaluation€ 700.00
-
3 working days upon order placementTarget Evaluation for Drug Discovery in Biopharmaceutical R&D: Basic Evaluation€ 350.00
-
July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.
€ 2550.00Original price was: € 2550.00.€ 1800.00Current price is: € 1800.00. -
July of 2022The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00
-
June of 2022The report evaluates opportunities for ROR1-targeted drug modalities within the competitive landscape€ 1050.00
-
May of 2022This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00
-
May of 2022This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00